Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFR? D842V Mutant GIST and Fourth-Line GIST

0
16

Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFR? D842V Mutant GIST and Fourth-Line GIST

LEAVE A REPLY

Please enter your comment!
Please enter your name here